LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

Home・Listă Acțiuni・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Deschisă

SectorSănătate

3.68 3.08

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.45

Maxim

3.68

Indicatori cheie
By Trading Economics
Venit	-9.4M -118M
Vânzări	-29M 6.5M
EPS	-0.22
Marjă de profit	-1,815.575
Angajați	600
EBITDA	-20M -109M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+105.57% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-270M 1.6B
Deschiderea anterioară	0.6
Închiderea anterioară	3.68

Sentimentul știrilor

By Acuity

100%

320 / 344 Clasament în Healthcare

Recursion Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

19 feb. 2026, 21:28 UTC

Achiziții, Fuziuni, Preluări

Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street. -- Barrons.com

19 feb. 2026, 10:27 UTC

Achiziții, Fuziuni, Preluări

Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street. -- Barrons.com

18 feb. 2026, 14:52 UTC

Achiziții, Fuziuni, Preluări

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia. -- Barrons.com

Comparație

Modificare preț

Recursion Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

105.57% sus

Prognoză pe 12 luni

Medie 7.38 USD 105.57%

Maxim 10 USD

Minim 5.5 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRecursion Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Recursion Pharmaceuticals Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

320 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.